Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada

BACKGROUND: Dupilumab, omalizumab, and mepolizumab are the three biologics currently approved for use in CRSwNP in Canada. Despite evidence of efficacy, their cost-effectiveness, which is a key factor influencing prescribing patterns, has not yet been compared to each other. METHODS: A cost-effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Michael, Kirubalingam, Keshinisuthan, Desrosiers, Martin Y., Kilty, Shaun J., Thamboo, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576384/
https://www.ncbi.nlm.nih.gov/pubmed/37838713
http://dx.doi.org/10.1186/s13223-023-00823-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576384/
https://www.ncbi.nlm.nih.gov/pubmed/37838713
http://dx.doi.org/10.1186/s13223-023-00823-1

Ejemplares similares